Skip to main content
 

Press Releases

March 8, 2021

Berkeley, CA, March 8, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that Rachel Haurwitz, Ph.D., Caribou’s President and Chief Executive Officer, will present a company overview at upcoming investor conferences in March.

March 3, 2021

Berkeley, CA, March 3, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing. Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.

In the News

CRISPR treating cancer, Rachel Haurwitz, Co-founder and CEO, Caribou Biosciences

April 15, 2021

“Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-based technologies, and has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems.”

Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products

February 23, 2021

“AbbVie and Caribou Biosciences, Inc have announced that the companies have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR) T-cell therapeutics.”

About Us

Pioneering the translation of CRISPR-Cas genome engineering into new medical therapies and bio-based products. Learn more. 

Contact Us

For media and investor inquiries and general information, click here.

Follow Us

Connect with us on Twitter for the latest news and updates. Click here.

Media Contact

Greg Kelley
Senior Vice President
Ogilvy
+1 (617) 461-4023
gregory.kelley@ogilvy.com